dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Briassoulis, E. Ch | en |
dc.contributor.author | Bai, M. C. | en |
dc.contributor.author | Fountzilas, George | en |
dc.contributor.author | Agnantis, Niki J. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Briassoulis, E. Ch | en |
dc.creator | Bai, M. C. | en |
dc.creator | Fountzilas, George | en |
dc.creator | Agnantis, Niki J. | en |
dc.date.accessioned | 2018-06-22T09:54:17Z | |
dc.date.available | 2018-06-22T09:54:17Z | |
dc.date.issued | 1995 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42284 | |
dc.description.abstract | The role of oncogenes in carcinoma of unknown primary site (CUP) has not yet been elucidated. In the present study the expression of the c-myc p62, ras p21 and c-erb B p185 oncoproteins were studied by a 3-step immunoperoxidase technique in 26 cases of CUP. Positive immunoreactivity was observed in 96% of the cases for c-myc, 92% for ras and in 65% for c-erb-2, with at least half of tumor cells labelled in 85%, 92% and 58% respectively. The degree of staining intensity was considered moderate or strong in more than half of the cases for all oncogene products. In conclusion, our results showed that patients with CUP have an extremely high overexpression of all three oncogenes studied. Nevertheless, the biological role of these overexpressed oncoproteins, their relationship with different histological or clinical parameters and their diagnostic or prognostic value need further evaluation. | en |
dc.language.iso | eng | en |
dc.source | Anticancer Research | en |
dc.subject | Article | en |
dc.subject | Human | en |
dc.subject | Neoplasms | en |
dc.subject | Adenocarcinoma | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Controlled study | en |
dc.subject | Female | en |
dc.subject | Middle aged | en |
dc.subject | Priority journal | en |
dc.subject | Clinical article | en |
dc.subject | Neoplastic | en |
dc.subject | Carcinoma | en |
dc.subject | Male | en |
dc.subject | Gene expression regulation | en |
dc.subject | Unclassified drug | en |
dc.subject | Tumor cell | en |
dc.subject | Oncogene | en |
dc.subject | Squamous cell | en |
dc.subject | Unknown primary | en |
dc.subject | Carcinoma | en |
dc.subject | Oncoprotein | en |
dc.subject | Human cell | en |
dc.subject | Immunoreactivity | en |
dc.subject | Oncogene c erb | en |
dc.subject | Oncogene c myc | en |
dc.subject | Oncogene ras | en |
dc.subject | Gene expression | en |
dc.subject | Neoplasm proteins | en |
dc.subject | Erbb-2 | en |
dc.subject | Receptor | en |
dc.subject | Protein p21 | en |
dc.subject | Immunoenzyme techniques | en |
dc.subject | Proto-oncogene proteins p21(ras) | en |
dc.subject | C-erbb-2 | en |
dc.subject | C-myc | en |
dc.subject | Carcinoma of unknown primary | en |
dc.subject | Oncogenes | en |
dc.subject | Protein p185 | en |
dc.subject | Protein p62 | en |
dc.subject | Proto-oncogene proteins c-myc | en |
dc.subject | Ras | en |
dc.title | Overexpression of C-myc, ras and C-erb B-2 oncoproteins in carcinoma of unknown primary origin | en |
dc.type | info:eu-repo/semantics/article | |
dc.description.volume | 15 | |
dc.description.issue | 6 B | en |
dc.description.startingpage | 2563 | |
dc.description.endingpage | 2567 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |